Accordingly, we conducted a subgroup analysis of EMPHASIS-HF to examine major clinical outcomes of EMPHASIS-HF according to background dose of ACEi (and ARB), β-blocker, and both classes of drug.
Methods

Study Patients
All randomized patients from the EMPHASIS-HF study contributed to this subgroup analysis. The characteristics of these patients have been well described previously, as have the inclusion and exclusion criteria of the study. 5 Briefly, to qualify for randomization in EMPHASIS-HF, patients had to be >55 years of age, have New York Heart Association class II symptoms, and an ejection fraction of no more than 30% (or 30%-35% if QRS duration >130 ms), as well as receiving standard background HF therapy, comprising ACEi, ARB (or both), as well as β-blocker at recommended or maximal tolerated doses. Investigators were encouraged to uptitrate patients to highest stable doses of these therapies before randomization into the EMPHASIS-HF study.
Dosing Equivalent of Background Drugs
A target daily dose was established based on approved dose ranges and targets for individual ACEi, ARBs, and β-blockers ( Table 1) . The percentage daily dose of the individual patient was determined based on the total daily dose expressed as a percentage of the target daily dose of each agent being taken at baseline (before randomization). From this, outcomes according to patients receiving less or greater than 50% target dose were derived.
Study Outcomes
Assessment was made according to target dose, with patients receiving ≤50% of target daily dose considered to be receiving low dose and >50% high dose. Patients not taking a particular drug class were considered to be in the low-dose group. Groups evaluated separately were as follows:
• ACEi (and ARB) ≥50%, versus <50% target dose.
• β-blocker ≥50%, versus <50% target dose.
• Both ACEi and β-blocker ≥50%, versus at least one of ACEi or β-blocker <50% target dose.
Outcomes evaluated according to background drug dose were the EMPHASIS-HF primary end point (time to first event of cardiovascular [CV] death or HF hospitalization) and all-cause mortality.
In addition, relevant safety end points (frequency of hyperkalemia, estimated glomerular filtration rate [eGFR], clinical hypotension) were also evaluated according to background drug dose.
Statistical Analysis
The following analyses are performed on the background drug groups defined above. Descriptive statistics are summarized for the baseline data, including demographics and relevant baseline data. The efficacy analyses on the primary end point (HF hospitalization/CV death) and all-cause mortality are performed using a Cox proportional hazards ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; bpm, beats per minute; eGFR, estimated glomerular filtration rate; HF, heart failure; and LVEF, left ventricular ejection fraction.
Overall P>0.05 between groups.
model, including treatment, subgroup, and treatment by subgroup interaction. In addition, the frequency of serum potassium ≥5.5 mmol/L and hypotension adverse event were analyzed using Fisher exact test, and eGFR and blood pressure data at end of study are also summarized.
Results
Main Study Results
The Eplerenone was overall well tolerated; however, there were increases compared with placebo (as expected) in rates of worsened renal function, hyperkalemia, and hypotension. However, there were no differences between groups in rate of adverse events, leading to permanent withdrawal of study drug.
Baseline Patient Characteristics According to Background Drug Dose
Key patient characteristics, when subdivided according to background drug and dose, are summarized in Tables 2-4 . ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; bpm, beats per minute; eGFR, estimated glomerular filtration rate; HF, heart failure; and LVEF, left ventricular ejection fraction.
In general, patients were well matched with regard to these key demographic characteristics, despite the number of patients in specific subgroups being relatively small in some circumstances. Table 5 summarizes the effect of eplerenone versus placebo on the study's primary end point (CV death/HF hospitalization) according to dose of background neurohormonal antagonist drug therapy. Specifically, there was no significant difference in this outcome according to high (>50%) versus low dose of ACEi (or ARB), β-blocker, or both ACEi (or ARB) and β-blocker. P values for interaction between high and low doses for the EMPHASIS-HF primary end point were not significant. The HRs for eplerenone versus placebo for the EMPHASIS-HF primary end point were as follows: ACEi/ ARB: high dose, 0.67; low dose, 0.65; β-blockers: high dose, 0.55; low dose, 0.72; both ACEi/ARB and β-blocker: high dose, 0.59; low dose, 0.68. Kaplan-Meier plots for this outcome in patients receiving high-and low-dose background therapy are shown in Figures 1 to 3. Table 6 summarizes the effect of eplerenone versus placebo on all-cause mortality according to dose of background neurohormonal antagonist drug therapy. Similar to the study's primary end point, there was no significant difference in this outcome according to high (>50%) versus low dose of ACEi (or ARB), β-blocker, or both ACEi (or ARB) and β-blocker. P values for interaction between high and low doses for allcause mortality were not significant. The HRs for eplerenone versus placebo for all-cause mortality were as follows: ACEi/ ARB: high dose, 0.77; low dose, 0.79; β-blockers: high dose, 0.71; low dose, 0.81; both ACEi/ARB and β-blocker: high dose, 0.83; low dose, 0.76. Table 7 summarizes the effect of eplerenone versus placebo on incident hyperkalemia according to dose of background neurohormonal antagonist drug therapy. As expected, there was a greater incidence of hyperkalemia in the eplerenone group compared with placebo. However, there was little evidence of greater absolute rate of hyperkalemia events in patients receiving high doses versus low doses of background agents. Furthermore, there was no significant interaction observed for HRs between high-and lowdose background therapy for ACEi (or ARB), β-blocker, or both agents. Table 8 summarizes the effect of eplerenone versus placebo on eGFR at end of study according to dose of background neurohormonal antagonist drug therapy. Overall, there was little difference in eGFR at end of study in the eplerenone group compared with placebo. Furthermore, there was little to no evidence of an increase in eGFR in patients receiving high doses versus low doses of background agents. Specifically, there was no significant interaction observed for HRs between high-and low-dose background therapy for ACEi (or ARB), β-blocker, or both agents. Table 9 summarizes the effect of eplerenone versus placebo on the clinical adverse events of hypotension or postural hypotension at end of study according to dose of background neurohormonal antagonist drug therapy. There was overall no significant increased risk of this adverse event with ACEi indicates angiotensin-converting enzyme inhibitor; BB, β-blocker; CV, cardiovascular; and HF, heart failure. eplerenone versus placebo, irrespective of receiving high-and low-dose background therapy for ACEi (or ARB), β-blocker, or both agents.
Efficacy End Points According to Background Drug Dose
Safety End Points According to Background Drug Dose
Discussion
The present analysis examined whether the beneficial effects of eplerenone observed in the overall EMPHASIS-HF study were maintained in the subgroup of patients receiving optimal best practice background drug therapy comprising use of high-dose ACEi (or ARB) or β-blocker or both. This analysis is of relevance to the drug management of systolic HF patients with New York Heart Association class II symptoms as well as being of considerable mechanistic interest. ACEi and β-blockers are well established as mandatory life-saving background therapy in such patients. 1 However, it is well established that not all patients are able to tolerate these medications, and those that do often cannot reach target doses of these therapies for reasons of intolerance and adverse events. In the EMPHASIS-HF study, 4 77% of patients were receiving an ACEi, 19% ARB, and 94% either agent or both. Similarly, 87% of patients were receiving β-blockers.
Predefined subgroup analysis has determined that patients receiving these background therapies derived similar benefit with eplerenone as regards the primary study end point (CV death or HF hospitalization) versus those who were not receiving these agents. 4 However, analysis according to dosing of these agents has not been previously performed within the EMPHASIS-HF cohort. This is of importance as the question arises as to whether the benefits of eplerenone are maintained in the setting of higher doses of these agents. Alternatively, it may be argued that the same outcome benefit may be achieved by simply increasing the dose of background medication. When use of ivabradine additional to β-blockers was examined in this way in SHIFT (Systolic Heart failure treatment with I f inhibitor ivabradine Trial), 6 the magnitude of benefit of ivabradine in patients receiving >50% of dose of β-blocker was substantially reduced in comparison with the overall population. In contrast, the present analysis of EMPHASIS-HF demonstrates that the HRs generated for CV death/HF hospitalization or for all-cause mortality with the MRA eplerenone were of similar magnitude above and below 50% target dose for ACEi (or ARB) or β-blocker. Furthermore, this benefit was maintained in patients who had >50% of dosing for both background agents. These findings support the concept that addition of an MRA to background high-dose ACEi and β-blockers provides substantial additional clinical outcome benefit. Although a head-to-head study of increasing dose of these background agents versus the addition of eplerenone has not yet been performed, these findings would suggest that eplerenone may be the preferred strategy in this regard. However, this was not formally tested in the EMPHASIS-HF study nor has it been studied in other trials of MRAs in HF.
As mentioned, this analysis is also of considerable mechanistic interest and importance. As mentioned, there was maintenance of the overall benefit observed with eplerenone in the subgroup receiving high-dose ACEi and β-blocker. These findings suggest that the aldosterone inhibitory effect of a conventional strategy is either suboptimal or associated with clinically relevant aldosterone escape. 7 These findings support the need for direct mineralocorticoid receptor blockade to maximize renin-angiotensin-aldosterone blockade and associated clinical benefits. However, serum aldosterone levels were not analyzed in the present analysis, so this remains a hypothesis still to be formally tested.
The results of this analysis are also of relevance to the ongoing debate regarding how best to maximize the benefits of neurohormonal blockade in various CV settings, but specifically in systolic chronic HF. It is, however, uncertain whether 2 or 3 (or more) neurohormonal blocking agents are the optimal approach when added to standard background treatment. 8 The data have been mixed in this regard. For example, the benefits of adding the ARB candesartan seemed to be preserved, irrespective of dose of ACEi background therapy in CHARM (Conduction in Heart Failure: Assessment of Reduction in Mortality and Morbidity)-Added. 9 In contrast, in Val-HeFT (Valsartan Heart Failure Trial), the beneficial effects of valsartan were progressively attenuated with increasing dose of background ACEi. 10 The data seem more clear-cut with MRA therapy; in both EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) 11 and now EMPHASIS-HF, the efficacy benefits of this strategy seem to be preserved in the setting of maximized background therapy.
With regard to safety, the present subgroup analysis evaluated hyperkalemia and renal function according to use of eplerenone versus placebo and background ACEi (or ARB) or β-blocker dose (as well as for both background agents combined). The findings of this subgroup analysis would suggest that 2 of the most feared adverse events of MRAs (hyperkalemia, worsened renal function) do not occur with significantly greater frequency when added to highdose (versus low-dose) background neurohormonal drug therapy. Analysis of the impact of background neurohormonal drug dose on incidence of hypotension or postural hypotension does however suggest a borderline increase in risk of this adverse event in patients receiving high-dose (>50% dose) ACEi or ACEi combined with β-blocker at high dose.
Given that HF guidelines worldwide recommend highest tolerated dose of ACEi and β-blockers, the findings of the present subgroup analysis suggest that efficacy of eplerenone is maintained additional to these recommended drugs and doses and that safety is not unduly compromised in this setting (ie, patients with systolic HF and mild symptoms). In summary, the present subgroup analysis of EMPHASIS-HF has found that MRA eplerenone provided substantial clinical benefit and acceptable safety, even in the setting of high-dose background ACEi (or ARB) or β-blocker or both. Thus, use of eplerenone should be strongly considered, irrespective of dose of background neurohormonal antagonist therapy in systolic HF patients with mild (New York Heart Association class II) symptoms.
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